170097-66-2 Usage
Description
2-TERT-BUTYL 6-METHYL 3,4-DIHYDROISOQUINOLINE-2,6(1H)-DICARBOXYLATE is a chemical compound belonging to the isoquinoline family. It is characterized by its unique molecular structure, which features a tert-butyl group at the 2-position and a methyl group at the 6-position. 2-TERT-BUTYL 6-METHYL 3,4-DIHYDROISOQUINOLINE-2,6(1H)-DICARBOXYLATE is an important intermediate in the synthesis of various pharmaceutical compounds, particularly those with potential applications in the treatment of cancer.
Uses
Used in Pharmaceutical Industry:
2-TERT-BUTYL 6-METHYL 3,4-DIHYDROISOQUINOLINE-2,6(1H)-DICARBOXYLATE is used as an intermediate for the synthesis of pyridyloxyacetyl tetrahydroisoquinoline compounds. These compounds act as NAMPT inhibitors, which are useful in the treatment of cancer. By inhibiting NAMPT, these compounds can potentially disrupt the energy metabolism of cancer cells, leading to their growth inhibition and eventual death.
Used in Cancer Treatment:
2-TERT-BUTYL 6-METHYL 3,4-DIHYDROISOQUINOLINE-2,6(1H)-DICARBOXYLATE is used as a key component in the development of novel cancer therapeutics. The compounds derived from this intermediate have shown potential in targeting specific enzymes and pathways involved in cancer cell growth and survival. By inhibiting these targets, the compounds can help in the treatment of various types of cancer, including solid tumors and metastasized cancers.
Check Digit Verification of cas no
The CAS Registry Mumber 170097-66-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,0,9 and 7 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 170097-66:
(8*1)+(7*7)+(6*0)+(5*0)+(4*9)+(3*7)+(2*6)+(1*6)=132
132 % 10 = 2
So 170097-66-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H21NO4/c1-16(2,3)21-15(19)17-8-7-11-9-12(14(18)20-4)5-6-13(11)10-17/h5-6,9H,7-8,10H2,1-4H3
170097-66-2Relevant articles and documents
INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT
-
Paragraph 00501-00502, (2021/12/28)
The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6
PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST
-
Paragraph 0101; 0117, (2017/07/29)
The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.
HETEROCYCLIC COMPOUND
-
Paragraph 0595, (2017/08/01)
The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.
